Since the outbreak of the epidemic, all over the country has lent a hand to Wuhan and a number of anti-epidemic materials have been sent there. Dongcheng Pharmaceuticals, as a listed pharmaceutical enterprise, is also duty bound to fight against the epidemic and support Wuhan promptly . Up to now, Dongcheng Pharmaceuticals has donated more than 9 million yuan to support the front line of anti-epidemic. Recently, Ms. Xin Hongbo, General Manager of the Group, accepted an exclusive interview with Shandong Economic Radio. The following is the interview record.

In recent days, the business community of our province has been fighting against the epidemic with practical actions to help Wuhan. Recently, Dongcheng Pharmaceuticals Group Co., Ltd. (Stock Code: 002675), a small and medium-sized board listed company, extended a helping hand to Hubei. At present, the company has donated more than 9 million yuan of medical materials to the epidemic area of Hubei. As one of the biochemical API production bases in China, how does Dongcheng Pharmaceuticals treat the relationship between economic benefits and social benefits? On February 5, Ms. Xin Hongbo, General Manager of Dongcheng Pharmaceuticals Group Co., Ltd., received a telephones interview on the program "Money Tree" of Economic Channel of Shandong Radio.    

On the left is Ms. Xin Hongbo, General Manager of Dongcheng Pharmaceuticals Group Co., Ltd. and on the right is Mingyue, Shandong Economic Radio reporter

Presenter: At the critical moment when the whole country overcame the difficulties, Dongcheng Pharmaceuticals extended a helping hand to Hubei. It is understood that Dongcheng Pharmaceuticals has donated more than 9 million yuan of medical materials to the epidemic area. Please introduce the relevant information to us.

Ms. Xin: Since the outbreak of new coronavirus pneumonia, we have paid great attention to it. On January 27, we set up an Epidemic Response and Disposal Working Group headed by the Chairman of the Board Mr. You Shouyi, which focused on how Dongcheng Pharmaceuticals took social responsibility after the outbreak of new coronavirus pneumonia and how to use our own resources to help Wuhan in the fastest and most effective way. Considering the advantages of the company's API sales to more than 40 countries around the world, we contacted some customers at home and abroad for the first time and purchased medical materials such as masks from all over the world. At present, masks worth 160,000 yuan purchased by the company have been sent to the epidemic area through Shanghai Pharmaceuticals Holding Co., Ltd. 

We also pay close attention to the drugs needed for the epidemic. We find that Ambroxol(an expectorant) and Hydrocortisone(a glucocorticoid), urgently needed in the epidemic area, are the products of our company. In order to deliver the drugs to the designated hospitals as soon as possible, we discussed with the headquarters of SinopharmHuarun, and directly donated Ambroxol and Hydrocortisone produced by our company to the designated hospitals with the help of their strong hospital distribution ability. On January 31, the first batch of self-produced anti-epidemic drugs with a value of 8.93 million yuan was sent out from the company and arrived at Shanghai Pharmaceuticals Holding Co., Ltd. on February 1. On February 2, these drugs arrived in Hubei. At present, the drugs are being delivered to the epidemic area hospital. The second batch of anti-epidemic drugs with a value of more than 80,000 yuan was sent out on February 1 and arrived at Huarun Beijing Company on February 2. Now, these drugs are also on their way to the hospital. 

Within the company, we have launched an initiative to all employees, calling on everyone to actively extend a helping hand to compatriots in the affected areas. At present, the company's employees have raised nearly 500,000 yuan for donation. After the donation, we will make a unified arrangement for donation.

Presenter: Dongcheng pharmaceutical extended a helping hand to Hubei province and interpreted the corporate responsibility and social responsibility with practical actions.As one of the production bases of biochemical API in China, how does your company view the relationship between economic benefit and social benefit? 

Ms.Xin：The characteristic of pharmaceutical companies is to provide cures for human diseases. This is a very special industry, which is oriented by social responsibility. Dongcheng has gone through 21 years of journey, and 2019 is the first year of Dongcheng next new 20 years. We propose the corporate development concept of "Same Mind, Same Direction, Same Action ", one of which is the concept of "Grow up with medical discipline, patient-centered". Dongcheng pharmaceutical is one of 6,000 pharmaceutical enterprises. Our understanding of economic and social benefits is that only pharmaceutical enterprises that dare to undertake social responsibilities can finally win good economic benefits.

Presenter: Dongcheng pharmaceutical was launched on the SME board in May 2012. In the past 8 years since its listing, the company has successfully realized the layout from biochemical API to nuclear pharmaceutical.How to view the development space of nuclear medicine market?

Ms. Xin: Since the beginning of Dongcheng's public listed in 2015, the company has proposed strategies for endogenous growth and epitaxial development, and found a broad market space for nuclear drugs in the process of epitaxial acquisition. 

Nuclear medicine has unique advantages in clinical diagnosis and treatment, and it can realize the integration of diagnosis and treatment, which is a very typical precision medical method. Nuclear medicine has a vast market space in the world, but compared with developed countries, there is still a huge gap in the level of nuclear medicine in China. Share with you two sets of data: the output value of nuclear technology applications in the United States has accounted for 3% of GDP, while China has only 0.25% of GDP; The inventory of PET / CTper million population is 4.39 units in USA, while China has only 0.17 , which is far below the level of developed countries. China's nuclear medicine has developed slowly for many years just because of these gaps. Private companies engaged in nuclear medicine are small and scattered, and their innovation and promotion capabilities are weak. The hospital ’s nuclear medicine department is still a weak department. Meanwhile, the nuclear medicine industry, and our entire nuclear medicine industry is not able to enjoy the national policy dividend.

After thoroughly understanding the overall status of China's nuclear medicine, Dongcheng Pharmaceutical repeatedly discussed and reached a consensus-we have the responsibility to integrate the Chinese nuclear medicine market quicklyso that China's nuclear medicine has a larger development platform. From 2015 to 2018, we quickly deployed, acquired 6 nuclear drug companies, and quickly grew into one of the duopoly in the nuclear drug field in China. In the future, we will continue to build nuclear drug platforms to promote nuclear drug innovation and meet clinical needs. 

The characteristic of nuclear medicine is the integration of diagnosis and treatment. It is a very typical precision medicine. It is called visible precision medicine. It has positive significance for the early prevention and treatment of tumors. The "Outline of Healthy China 2030 Plan" states that precision treatment and early prevention and early treatment are both national strategies, and we expect that nuclear medicine has entered the fas track of development in China. Dongcheng Pharmaceutical is currently rapidly introducing core talents, reserve core experts, building production bases, laying out sales networks, breaking through technical barriers, and realizing domestic production of raw materials. After our years of operation and accumulation, we have built a very solid and competitive platform, with the ability to talk with international nuclear drug companies, and some international nuclear drug giants have extended us olive branches of international cooperation.

The development of nuclear medicine in China has huge clinical requirements, and the nuclear medicine market is growing at an annual rate of more than 25%, which is far beyond the average growth rate of the pharmaceutical industry. Dongcheng people firmly believe that we will definitely improve the ability of nuclear medicine to serve Chinese clinical patients and realize the great revival of China's nuclear medicine industrythrough our continuous efforts.t